Efficacy control of therapy using circulating epithelial tumor cells (CETC) as "liquid biopsy": trastuzumab in HER2/neu-positive breast carcinoma
about
Circulating tumor cells in breast cancer.Insulin-like growth factor receptor I (IGF-IR) and vascular endothelial growth factor receptor 2 (VEGFR-2) are expressed on the circulating epithelial tumor cells of breast cancer patients.Quantification of rare cancer cells in patients with gastrointestinal cancer by nanostructured substrate.Heterogeneity of ERα and ErbB2 Status in Cell Lines and Circulating Tumor Cells of Metastatic Breast Cancer Patients.Discordance in HER2 gene amplification in circulating and disseminated tumor cells in patients with operable breast cancer.The emerging role of circulating tumor cells in breast cancer.Molecular characterization of circulating tumor cells in breast cancer: challenges and promises for individualized cancer treatment.Dielectrophoresis has broad applicability to marker-free isolation of tumor cells from blood by microfluidic systems.Sensitive detection of PD-L1 expression on circulating epithelial tumor cells (CETCs) could be a potential biomarker to select patients for treatment with PD-1/PD-L1 inhibitors in early and metastatic solid tumors.Establishment and Application of Prostate Cancer Circulating Tumor Cells in the Era of Precision Medicine.Novel Strategies on Personalized Medicine for Breast Cancer Treatment: An Update.Estrogen receptor-α promoter methylation is a biomarker for outcome prediction of cisplatin resistance in triple-negative breast cancer.
P2860
Q34077349-E9DC1B44-CD59-46ED-AEEC-2C9D1AE3FFBAQ34590296-13D00368-C0F2-4F5F-BDED-B3D23269469CQ35028840-26648829-B596-439E-976D-865E44D636A2Q36525788-3A54C659-757D-46FE-82E1-DBD4EF93F114Q36804888-1BF79803-01EC-4BDF-B17F-CA959C535A23Q37978566-3739992C-550B-4391-9CD4-BE7C1374ECADQ38018253-7A76EB30-11A0-4D33-82B8-A1BFEC8B05DDQ41877445-C4BC9001-3955-490D-881E-EF5E9B46EA4AQ42700740-119724C0-F7BD-493A-A730-A4A1BAA7961AQ47110040-8AD7A622-43F7-44EE-B903-3050194B7949Q47115287-E6B141FF-BB03-433D-85DD-D385E435B943Q49875019-BCB4215D-F4DC-4F64-8F42-6530E9864CE3
P2860
Efficacy control of therapy using circulating epithelial tumor cells (CETC) as "liquid biopsy": trastuzumab in HER2/neu-positive breast carcinoma
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
Efficacy control of therapy us ...... /neu-positive breast carcinoma
@ast
Efficacy control of therapy us ...... /neu-positive breast carcinoma
@en
type
label
Efficacy control of therapy us ...... /neu-positive breast carcinoma
@ast
Efficacy control of therapy us ...... /neu-positive breast carcinoma
@en
prefLabel
Efficacy control of therapy us ...... /neu-positive breast carcinoma
@ast
Efficacy control of therapy us ...... /neu-positive breast carcinoma
@en
P2093
P2860
P1476
Efficacy control of therapy us ...... /neu-positive breast carcinoma
@en
P2093
A K Gellner
I B Runnebaum
J Wotschadlo
Katharina Pachmann
P2860
P2888
P304
P356
10.1007/S00432-011-1000-6
P577
2011-07-08T00:00:00Z